(Street) HOOFDDORP

**P7** 

2132WT

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ΚI	IIES	AND EXCHANGE	COMMISSION
		D 0 00=10	

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		Reporting Person*						ker or Tradir						ationship of F		Person	(s) to Issue	er
BAYER	R HEALT	HCARE LLC	2		Senti	Bioscie	ence	es, Inc. [	SNT	IJ			Crieck	Director	,	V	10% Ov	
(Last)	(F	irst)	(Middle)		3. Date		Trans	saction (Mor	ith/Da	y/Year)			1	Officer (g below)	ive title		Other (s below)	specify
100 BAY	ER BOULI	EVARD			12/09/	2024												
(Street) WHIPPA	NY N	J	07981		4. If Am	nendment, [	Date o	of Original F	iled (N	/lonth/Da	y/Year)		6. Indiv		d by One	Reporti	ng Person	
(City)	(S	tate)	(Zip)												,			
			Table I - Non	-Deriva	tive	Securitie	s A	cquired,	Disp	osed	of, or E	Benefi	cially O	wned				
1. Title of S	ecurity (Inst	r. 3)		2. Transad Date (Month/Da		2A. Deen Execution if any (Month/D	n Dat	Code (		4. Secur Dispose	rities Acq ed Of (D)	uired (A) (Instr. 3,	or 4 and 5)	5. Amount Securities Beneficially Following I	/ Owned Reported	Form:	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	t (	A) or D)	Price	Transaction (Instr. 3 and				(Instr. 4)
Common	Stock													587,8	348	1	<b>D</b> <sup>(1)</sup>	
			Table II - D					quired, D s, option						ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transa Code (		5. Number Derivative Securities Acquired ( or Dispose (D) (Instr. 3 and 5)	A) ed of	6. Date Exe Expiration (Month/Day	Date		Securiti			8. Price of Derivative Security (Instr. 5)	9. Numb derivativa Securiti Benefici Owned Followin Reporte	ve es ially ng	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		piration te	Title		int or per of es		Transac (Instr. 4)	tion(s)		
Series A Convertible Preferred Stock	(2)	12/09/2024		P		2,222		(2)		(2)	Commo Stock	n 2,22	2,000(2)	(3)	2,2	22	D <sup>(1)</sup>	
Warrant	\$2.3	12/09/2024		P		3,333,000		(4)	12/	/09/2029	Commo Stock	n 3,3	33,000	(3)	3,330	,000	D <sup>(1)</sup>	
		Reporting Person*				1											,	1
BAYER	RHEALT	HCARE LLC	<u>2</u>															
(Last) 100 BAY	ER BOULI	(First) EVARD	(Middle)															
(Street) WHIPPA	NY	NJ	07981															
(City)		(State)	(Zip)															
	d Address of JS Holdir	Reporting Person*																
(Last)	ER BOULI	(First)	(Middle)															
(Street) WHIPPA	NY	NJ	07981															
(City)		(State)	(Zip)															
		Reporting Person*				1												
						1												

(City)	(State)	(Zip)
1. Name and Address of BAYER AKTII		
(Last) BAYERWERK, KA	(First) AISER-WILH	(Middle) IELM-ALLEE 1
(Street) LEVERKUSEN	2M	51368
(City)	(State)	(Zip)

## **Explanation of Responses:**

- 1. The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
- 2. Each share of Series A Convertible Preferred Stock ("Series A") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A.
- 3. The reported securities include shares of Series A and warrants purchased by the reporting person for \$2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased.
- 4. The warrant becomes exercisable once the Issuer's stockholders first approve the issuance of the Issuer's common stock underlying the warrants in excess of the limitations imposed by Rule 5635 of the Nasdaq Stock

Bayer HealthCare LLC, By: /s/ Priyal Patel, Name: Priyal Patel, 12/11/2024 Title: Treasurer Bayer US Holding LP, By: /s/ Priyal Patel, Name: Priyal Patel, 12/11/2024 Title: Treasurer Bayer World Investments B.V., By: /s/ Kati Schnuerer, Name: 12/11/2024 Kati Schnuerer, Title: Managing Director Bayer Aktiengesellschaft, By: /s/ Thomas Hoffmann, Name: 12/11/2024 Thomas Hoffmann, Title: Head of Treasury \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.